SOAANZ (torsemide)
Development Insights
Details
- Status
- Discontinued
- First Approved
- 2021-06-14
- Patent Cliff
- 2033
- Routes
- ORAL
- Dosage Forms
- TABLET
SOAANZ Approval History
What SOAANZ Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06708611 EXTOR-HF | SAR065-324 | Ph 4 | withdrawn | A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs |
| NCT03296813 TRANSFORM-HF results posted | Pro00080595 U01HL125511-01A1 | Ph 3 | completed | TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure |
| NCT05093621 TFO results posted | 2000029589 | Ph 3 | completed | Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure |
| NCT06218199 DART-HA | Dart-HA | Ph 4 | recruiting | Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts |
| NCT03187509 | 2017-7615 | Ph 4 | completed | Weight-Based Torsemide Dosing in Subjects With Heart Failure |
| NCT02813551 TROPHY results posted | HSC-MS-16-0198 | Ph 2 | completed | ToRsemide for pOstpartum HYpertension |
| NCT01558674 results posted | 7145-011 | Ph 1 | terminated | A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011) |
| NCT01788254 IKP243 | IKP243 2011-002291-16 | Ph 1 | completed | Open Label Study for the Functional Characterization of Drug Metabolism and Transport |
| NCT01845194 | TWINS-II-v1.9 | Ph 1 | completed | Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SOAANZ FDA Label Details
SOAANZ Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for SOAANZ
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2033
- • 6 active patents
Trial Analysis
- • 9 total trials
- • Stage: Declining
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment